0R15 8539.0 2.1534% 0R1E 8600.0 3.3654% 0M69 None None% 0R2V 190.25 -0.1312% 0QYR 1345.5 2.0871% 0QYP 424.0 0.5931% 0LCV 146.6464 -1.3147% 0RUK None None% 0RYA 1631.0 -0.6094% 0RIH 171.3 0.9131% 0RIH 174.9 2.1016% 0R1O 186.0 9820.0% 0R1O None None% 0QFP None None% 0M2Z 298.3 -0.6495% 0VSO None None% 0R1I None None% 0QZI 474.5 0.6363% 0QZ0 220.0 0.0% 0NZF None None%

Codexis Inc.

GB 0I0X

3.7712GBP
0.03(0.80%)

Last update at 2024-05-16T15:39:00Z

Day Range

3.683.78
LowHigh

52 Week Range

1.476.88
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -33.31600M -21.09000M -23.67100M -11.91800M -10.91500M
Minority interest - - - - -
Net income -33.59200M -21.27900M -24.01000M -11.93500M -10.87800M
Selling general administrative 51.87M 49.02M 34.75M 31.00M 29.29M
Selling and marketing expenses 0.30M 0.30M 0.30M 0.50M -
Gross profit 20.46M 26.63M 11.13M 18.95M 47.97M
Reconciled depreciation - - - - -
Ebit -31.71400M -22.69700M -23.92000M -12.54900M -11.29500M
Ebitda -26.29400M -19.47800M -21.81800M -10.76200M -
Depreciation and amortization 5.42M 3.22M 2.10M 1.79M -
Non operating income net other - - - - -
Operating income -31.71400M -22.69700M -23.92000M -12.54900M -11.29500M
Other operating expenses 173.35M 126.30M 93.13M 81.66M -
Interest expense - 0.00000M 0.00000M 0.00000M 0.00000M
Tax provision - - 0.34M 0.02M -0.03700M
Interest income - - 0.41M 1.29M 0.67M
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.28M 0.19M 0.34M 0.02M -0.03700M
Total revenue 138.59M 104.75M 69.06M 68.46M 60.59M
Total operating expenses 55.22M 48.17M 35.20M 32.16M -
Cost of revenue 118.13M 78.13M 57.93M 49.51M 12.62M
Total other income expense net -1.60200M 1.61M 0.25M 0.63M -
Discontinued operations - - - - -
Net income from continuing ops - - - - -
Net income applicable to common shares -33.59200M -21.27900M -24.01000M -11.93500M -10.87800M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 250.39M 246.38M 221.65M 149.07M 79.28M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 6.01M 6.28M 4.05M 3.18M -
Total liab 105.60M 81.99M 51.54M 43.56M 22.98M
Total stockholder equity 144.80M 164.39M 170.10M 105.52M 56.31M
Deferred long term liab 0.02M 0.06M 0.09M - 0.04M
Other current liab 45.82M 30.38M 22.01M 12.77M 5.70M
Common stock 0.00600M 0.00600M 0.00600M 0.00600M 0.00500M
Capital stock - - - - -
Retained earnings -421.29000M -387.69800M -366.41900M -342.40900M -330.47400M
Other liab 18.25M 5.06M 4.24M 3.22M 4.80M
Good will 3.24M 3.24M 3.24M 3.24M 3.24M
Other assets 1.87M 1.80M 1.36M 1.24M 2.50M
Cash 113.98M 116.80M 149.12M 90.50M 53.04M
Cash and equivalents - - - - -
Total current liabilities 49.07M 33.37M 24.98M 15.39M 18.11M
Current deferred revenue - - - - -
Net debt -113.98400M -116.79700M -149.11700M -90.49800M -
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - 0.06M
Other stockholder equity 566.08M 552.08M 536.52M 447.92M -
Property plant equipment 61.88M 65.46M 31.18M 30.39M 4.76M
Total current assets 162.89M 161.89M 184.42M 114.20M 68.20M
Long term investments - - - - -
Net tangible assets 141.56M 161.15M 166.86M 102.28M 53.06M
Short term investments - - 1.00M - -
Net receivables 40.87M 37.65M 29.29M 20.16M 13.50M
Long term debt - - - - -
Inventory 2.03M 1.16M 0.96M 0.37M 0.59M
Accounts payable 3.25M 3.00M 2.97M 2.62M 3.05M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -85.62800M -82.70000M -35.86700M -33.62800M -
Deferred long term asset charges - - - - -
Non current assets total 85.63M 82.70M 35.87M 33.63M -
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -5.30000M -7.63000M -2.00000M 0.06M 0.06M
Change to liabilities 24.73M 1.57M 2.85M -6.67100M -11.15500M
Total cashflows from investing activities -13.57800M -21.42200M -5.74800M -3.66500M -2.76600M
Net borrowings - - -0.06000M -0.24200M -0.23800M
Total cash from financing activities -0.57500M 3.77M 80.81M 53.96M 38.57M
Change to operating activities 0.94M 0.16M 2.58M -0.32900M -0.21100M
Net income -33.59200M -21.27900M -24.01000M -11.93500M -10.87800M
Change in cash -2.86900M -31.92200M 58.60M 37.74M 21.71M
Begin period cash flow 118.89M 150.82M 92.22M 54.48M -
End period cash flow 116.03M 118.89M 150.82M 92.22M 54.48M
Total cash from operating activities 11.28M -14.26700M -16.46400M -12.56000M -14.09400M
Issuance of capital stock - - - - -
Depreciation 10.25M 5.95M 4.55M 4.56M 1.15M
Other cashflows from investing activities - - -2.00000M 0.07M 0.00200M
Dividends paid - - - - -
Change to inventory -0.86900M -0.19600M -0.59300M 0.22M 0.45M
Change to account receivables -3.22500M -9.15600M -8.72300M -5.86700M -1.42400M
Sale purchase of stock -1.48800M -1.20600M -1.25700M -2.85000M 42.18M
Other cashflows from financing activities 0.91M 4.97M 82.12M 57.05M -0.18000M
Change to netincome 13.05M 8.69M 6.88M 7.47M 7.98M
Capital expenditures 8.31M 13.83M 3.75M 3.73M 2.77M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -4.09400M -9.35200M -9.31600M -5.65000M -12.34300M
Stock based compensation 14.53M 11.59M 7.73M 6.94M -
Other non cash items 24.19M -1.17600M 4.58M -6.47500M -
Free cash flow 2.98M -28.09500M -20.21200M -16.29000M -

Fundamentals

  • Previous Close 3.74
  • Market Cap151.69M
  • Volume691
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-59.40400M
  • Revenue TTM73.96M
  • Revenue Per Share TTM1.10
  • Gross Profit TTM 20.46M
  • Diluted EPS TTM-0.32

Peer Comparison

Sector: Industry:

Company Change (GBP) Price (GBP) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
0I0X
Codexis Inc.
0.03 0.80% 3.77 - - 0.02 -
0LCV
Taiwan Semiconductor Manufacturing Co. Ltd. ADR
-1.9536 1.31% 146.65 0.20 - 0.01 -
0RIH
Alphabet Inc Class A
1.55 0.91% 171.30 - - - -
0M2Z
Equinor ASA
-1.95 0.65% 298.30 - - - -
0QZI
Facebook Inc. Cl A
3.00 0.64% 474.50 - - - -

Reports Covered

Stock Research & News

Profile

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Codexis Inc.

200 Penobscot Drive, Redwood City, CA, United States, 94063

Key Executives

Name Title Year Born
Dr. Stephen George Dilly MBBS, Ph.D. Pres, CEO & Director 1960
Mr. Ross Taylor Jr., M.B.A. Sr. VP & CFO 1963
Mr. John J. Nicols Director & Strategic Advisor 1964
Mr. Kevin Norrett M.B.A., M.S. Chief Operating Officer 1973
Ms. Margaret Fitzgerald J.D. Chief Legal and Compliance Officer, Gen. Counsel & Sec. NA
Ms. Asli Aras Ph.D. VP & Head of Corp. Devel. NA
Ms. Karen Frechou-Armijo Sr. VP & Head of HR NA
Mr. Rob Wilson Ph.D. Sr. VP & GM of Performance Enzymes NA
Dr. Karl A. Schoene Ph.D. Sr. VP of Devel. & Operations NA
Dr. Stefan Lutz Ph.D. Sr. VP of Research NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions